MedTrace Logo

Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

NCT04221256 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2021-07-23

No results posted yet for this study

Summary

The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke.

Conditions

  • Stroke, Ischemic

Interventions

DRUG

Administration of SSRI escitalopram

Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation

BEHAVIORAL

Paired Associative stimulation

Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.

DRUG

Administration of Placebo

Participants will be administered a placebo prior to paired associative stimulation

Sponsors & Collaborators

  • Burke Medical Research Institute

    lead OTHER

Principal Investigators

  • Tomoko Kitago, MD · Winifred Masterson Burke Medical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-11
Primary Completion
2021-02-09
Completion
2021-02-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221256 on ClinicalTrials.gov